Drug Profile

APB B007

Alternative Names: APB-B-007

Latest Information Update: 10 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kangwon National University
Developer APITBIO
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; Neural cell adhesion molecule L1 modulators; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Feb 2025 Biotheus has been acquired by BioNTech
02 Dec 2022 Early research in Solid tumours in South Korea (Parenteral) prior to December 2022 (ApitBio pipeline, December 2022)
15 Sep 2022 APITBIO signs a pre-agreement with Biotheus to jointly develop APB B007 for Solid tumours

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com